UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000047330
Receipt number R000053980
Scientific Title A Prospective Natural History Study of Patients with Intractable Venous Malformation and Klippel-Trenaunay Syndrome
Date of disclosure of the study information 2022/04/01
Last modified on 2022/03/30 18:03:32

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A Prospective Natural History Study of Patients with Intractable Venous Malformation and Klippel-Trenaunay Syndrome

Acronym

A Prospective Natural History Study of Patients with Intractable Venous Malformation and Klippel-Trenaunay Syndrome

Scientific Title

A Prospective Natural History Study of Patients with Intractable Venous Malformation and Klippel-Trenaunay Syndrome

Scientific Title:Acronym

A Prospective Natural History Study of Patients with Intractable Venous Malformation and Klippel-Trenaunay Syndrome

Region

Japan


Condition

Condition

Venous malformation and Klippel-Trenaunay Syndrome

Classification by specialty

Medicine in general Surgery in general Pediatrics
Dermatology Orthopedics Radiology
Plastic surgery

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To follow the natural history of patients either with venous malformation (VM) or Klippel-Trenaunay Syndrome (KTS) for 6 months.

Basic objectives2

Others

Basic objectives -Others

To obtain a benchmark to design a clinical trials to assess safety and efficacy of novel therapeutic candidates in patients with VM and KTS.

Trial characteristics_1

Others

Trial characteristics_2

Others

Developmental phase

Not applicable


Assessment

Primary outcomes

Change rate in the target lesion volume from baseline to Day 180

Key secondary outcomes

Changes in the following endpoints from baseline to Day 180.
-Severity (Appearance, function and others according to Hemangioma and Vascular Malformation Severity Classification created by Mimura group of Japanese Ministry of Health, Labor and Welfare)
-Pain score (visual analog scale [VAS])
-Quality of Life (PedsQL, SF-36)
-Performance Status (Lansky play-performance scale or Karnofsky Performance Status)
-History of infection
-Circumference of the lesion (if available)
-Photograph of lesion site (if available)
-Biomarkers (D-dimer, platelet count, fibrinogen)


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1)Male or female patients at any age
2)Patients diagnosed with intractable VM or KTS following the diagnostic criteria (Japanese clinical practice guidelines for vascular anomalies 2017, Japan Intractable Disease Information Center, and Information Center for Specific Pediatric Chronic Diseases, Japan)
3)Presence of symptom(s) (e.g., pain, fever, infection, bleeding, disfigurement, etc.)
4)Patients having refractory disease (e.g., poor response to standard of care [e.g., analgesics, oral medications, compression stockings, sclerotherapy, and surgical resection])
5)Patients who have taken or plan to take Magnetic resonance imaging (MRI) scan in their daily practice
6) Patients who have provided written consent or assent (for children, consent by their legal guardians is acceptable). Signed informed consent is obtained either from patient (aged 20 and older), patient and parent/guardian (aged from 16 to 19), or parent/guardian (aged younger than 16).

Key exclusion criteria

1)Patients for whom MRI scan is difficult or impossible to perform and whose lesions are difficult to be evaluated by MRI due to artifacts (e.g., patients who have electronic devices in their body such as cardiac pacemakers, implantable cardioverter defibrillators (ICDs), ventricular shunts, orthodontic appliances, cochlear implants neurostimulators or spinal cord stimulators, who need sedation for MRI scan but have risk to use it, and who are uncomfortable in closed or dark areas, etc.)
2)Patients whose lesion volume is difficult to measure by MRI (e.g., lesions for which the long and short diameters of the maximum cross-sectional area to be evaluated are unclear).
3)Patients who received invasive treatment including sclerotherapy or resection surgery for the target lesions within 12 weeks at obtaining consent, regardless of the classification of treatment, clinical research, or clinical trial
4)Patients who participated in any clinical trials (excluding observational studies) within 12 weeks at obtaining consent.
5)Patients who are judged by the investigator not to be eligible for the study (e.g., problems with cognitive function, comprehension, or compliance with hospital visits).

Target sample size

100


Research contact person

Name of lead principal investigator

1st name Hiroshi
Middle name
Last name Nagabukuro

Organization

ARTham Therapeutics Inc.

Division name

-

Zip code

2310023

Address

24-8 Yamashita-cho, Naka-ku, Yokohama, Kanagawa, Japan

TEL

0452258858

Email

hiroshi.nagabukuro@arthamther.com


Public contact

Name of contact person

1st name Kanako
Middle name
Last name Kuniyeda

Organization

ARTham Therapeutics Inc.

Division name

Discovery Science

Zip code

2310023

Address

24-8 Yamashita-cho, Naka-ku, Yokohama, Kanagawa, Japan

TEL

0452258858

Homepage URL


Email

kanako.kuniyeda@arthamther.com


Sponsor or person

Institute

ARTham Therapeutics Inc.

Institute

Department

Personal name



Funding Source

Organization

Japan Agency for Medical Research and Development

Organization

Division

Category of Funding Organization

Japanese Governmental office

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Osaka National Hospital

Address

2-chome-1-14 Hoenzaka, Chuo-ku, Osaka, Osaka

Tel

0669421331

Email

408-chiken@mail.hosp.go.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

国立成育医療研究センター、岐阜大学医学部附属病院、神戸大学医学部附属病院、大分大学医学部附属病院、順天堂大学医学部附属浦安病院、東北大学病院、慶應義塾大学病院、東海大学医学部付属病院、北海道大学病院、大阪大学医学部附属病院、和歌山県立医科大学


Other administrative information

Date of disclosure of the study information

2022 Year 04 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

34

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2019 Year 01 Month 30 Day

Date of IRB

2019 Year 01 Month 30 Day

Anticipated trial start date

2019 Year 06 Month 19 Day

Last follow-up date

2021 Year 04 Month 08 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

To follow the natural history of patients either with venous malformation (VM) or Klippel-Trenaunay Syndrome (KTS) for 6 months.


Management information

Registered date

2022 Year 03 Month 30 Day

Last modified on

2022 Year 03 Month 30 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000053980


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name